Ampliphi restates financial statements

|About: Ampliphi Biosciences C... (APHB)|By:, SA News Editor

Ampliphi Biosciences (OTCQB:APHB +11.4%) restates its financial statements for the quarters ended September 30, 2013, December 31, 2013 and March 31, 2014 and for the year ended December 31, 3013 due to non-cash adjustments related to its Series B Preferred Stock dividend clause to reflect its treatment as a compound derivative.

It will restate its financials for the year ended December 31, 2013 due to a reclassification of in-process R&D related to its acquisition of Biocontrol Ltd.

The financials for the years ended December 31, 2011, 2012 and 2013 will be revised to recognize amortization of certain patents.